BSBodil Cecillie Sondergaard

Bodil Cecillie Sondergaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bodil Cecillie Sondergaard has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus

    by B.C. Sondergaard, P. Catala-Lehnen, A.K. Huebner, A.-C. Bay-Jensen, T. Schinke, K. Henriksen, S. Schilling, M. Haberland, R.H. Nielsen, M. Amling, et al.


  • Open Access

    Identification of the calcitonin receptor in osteoarthritic chondrocytes

    by Toni Segovia-Silvestre, Caroline Bonnefond, Bodil C Sondergaard, Tjorbjoern Christensen, Morten A Karsdal, Anne C Bay-Jensen

    Preclinical and clinical studies have shown that salmon calcitonin has cartilage protective effects in joint degenerative diseases, such as osteoarthritis (OA). However, the presence of the calcitonin receptor (CTR) in articular cartilage chondrocytes is yet to be identified. In this study, we sought to further investigate the expression of the CTR in naïve human OA articular chondrocytes to gain further confirmation of the existents of the CTR in articular cartilage.


  • Mice over-expressing salmon calcitonin have strongly attenuated bone and cartilage changes after destabilization of the medial meniscus

    by B.C. Sondergaard⁎, T. Schinke, A.K. Huebner, P. Catala-Lehnen, S. Schilling, M. Haberland, R.H. Nielsen, M.A. Karsdal

  • Open Access

    Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes

    by Bodil-Cecilie Sondergaard, Suzi H Madsen, Toni Segovia-Silvestre, Sarah J Paulsen, Thorbjorn Christiansen, Christian Pedersen, Anne-Christine Bay-Jensen, Morten A Karsdal

    Calcitonin has been demonstrated to have chondroprotective effects under pre-clinical settings. It is debated whether this effect is mediated through subchondral-bone, directly on cartilage or both in combination. We investigated possible direct effects of salmon calcitonin on proteoglycans and collagen-type-II synthesis in osteoarthritic (OA) cartilage.


  • Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

    by Anne-Christine Bay-Jensen, Suzi Hoegh-Madsen, Erik Dam, Kim Henriksen, Bodil Cecillie Sondergaard, Philippe Pastoureau, Per Qvist, Morten A. Karsdal

    Osteoarthritis (OA) is a disease of the entire joint. Different treatment strategies for OA have been proposed and tested clinically without the desired efficacy. One reason for the scarcity of current chondroprotective agents may be the insufficient understanding of the patho-physiology of the joint and whether the joint damage is reversible or irreversible. In this review, we compile emerging data on cellular and pathological aspects of OA, and ask whether these data could give clue to when cartilage degradation is reversible and whether a point-of-no-return exists. We highlight different stages of OA, and speculate whether different intervention strategies (e.g. DMOAD vs. SMOADs) may only be efficacious at distinct stages of OA.


  • Open Access

    Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments

    by Bijue Wang, Pingping Chen, Anne-Christine B Jensen, Morten A Karsdal, Suzi H Madsen, Bodil-Cecilie Sondergaard, Qinlong Zheng, Per Qvist

    Progressive loss of articular cartilage is a central hallmark in many joint disease, however, the relative importance of individual proteolytic pathways leading to cartilage erosion is at present unknown. We therefore investigated the time-dependant release ex vivo of MMP- and aggrecanase-derived fragments of aggrecan and type II collagen into the supernatant of bovine cartilage explants cultures using neo-epitope specific immunoassays, and to associate the release of these fragments with the activity of proteolytic enzymes using inhibitors.


  • Open Access

    Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity

    by Morten A Karsdal, Suzi H Madsen, Claus Christiansen, Kim Henriksen, Amanda J Fosang, Bodil C Sondergaard

    Introduction: Physiological and pathophysiological cartilage turnover may coexist in articular cartilage. The distinct enzymatic processes leading to irreversible cartilage damage, compared with those needed for continuous self-repair and regeneration, remain to be identified. We investigated the capacity of repair of chondrocytes by analyzing their ability to initiate an anabolic response subsequent to three different levels of catabolic stimulation. Methods: Cartilage degradation was induced by oncostatin M and tumour necrosis factor in articular cartilage explants for 7, 11, or 17 days. The catabolic period was followed by 2 weeks of anabolic stimulation (insulin growth factor-I). Cartilage formation was assessed by collagen type II formation (PIINP). Cartilage degradation was measured by matrix metalloproteinase (MMP) mediated type II collagen degradation (CTX-II), and MMP and aggrecanase mediated aggrecan degradation by detecting the 342FFGVG and 374ARGSV neoepitopes. Proteoglycan turnover, content, and localization were assessed by Alcian blue. Results: Catabolic stimulation resulted in increased levels of cartilage degradation, with maximal levels of 374ARGSV (20-fold induction), CTX-II (150-fold induction), and 342FFGVG (30-fold induction) (P < 0.01). Highly distinct protease activities were found with aggrecanase-mediated aggrecan degradation at early stages, whereas MMP-mediated aggrecan and collagen degradation occurred during later stages. Anabolic treatment increased proteoglycan content at all time points (maximally, 250%; P < 0.001). By histology, we found a complete replenishment of glycosaminoglycan at early time points and pericellular localization at an intermediate time point. In contrast, only significantly increased collagen type II formation (200%; P < 0.01) was observed at early time points. Conclusion: Cartilage degradation was completely reversible in the presence of high levels of aggrecanase-mediated aggrecan degradation. After induction of MMP-mediated aggrecan and collagen type II degradation, the chondrocytes had impaired repair capacity.


  • Open Access

    Patients with rheumatoid arthritis have an altered circulatory aggrecan profile

    by Jean C Rousseau, Eren U Sumer, Gert Hein, Bodil C Sondergaard, Suzi H Madsen, Christian Pedersen, Thomas Neumann, Andreas Mueller, Per Qvist, Pierre Delmas, et al.

    Background: Rheumatoid arthritis (RA) is a chronic auto-immune disease with extensive articular cartilage destruction. Aggrecan depletion, mediated by aggrecanases is one of the first signs of early cartilage erosion. We investigated, whether measurement of aggrecan and fragments thereof in serum, could be used as biomarkers for joint-disease in RA patients and furthermore characterized the fragments found in the circulation. Methods: The study consisted of 38 patients, 12 males (62.2 ± 16.0 years) and 26 females (59.8 ± 20.7 years) diagnosed with RA: 41.5 ± 27.5 mm/h erythrocyte sedimentation rate (ESR), 38.4 ± 34.7 mg/ml C-reactive protein (CRP) and 4.8 ± 1.7 disease activity score (DAS) and 108 healthy age-matched controls. Aggrecan levels were measured using two immunoassays, i.e. the 374ARGSVI-G2 sandwich ELISA measuring aggrecanase-mediated aggrecan degradation and the G1/G2 sandwich assay, detecting aggrecan molecules containing G1 and/or G2 (total aggrecan) We further characterized serum samples by western blots, by using monoclonal antibodies F-78, binding to G1 and G2, or by BC-3, detecting the aggrecanase-generated N-terminal 374ARGSVI neo-epitope. Results: Total aggrecan levels in RA patients were significantly decreased from 824.8 ± 31 ng/ml in healthy controls to 570.5 ± 30 ng/ml (31% decrease, P < 0.0001), as measured by the G1/G2 ELISA. Western blot analysis with F-78 showed one strong band at 10 kDa, and weaker bands at 25 and 45 kDa in both healthy controls and RA patients. In contrast, staining for aggrecanase-activity revealed only one strong band in RA patients of 45 kDa. Conclusion: This is the first study, which characterizes different aggrecan fragments in human serum. The data strongly suggests that total aggrecan levels, i.e. aggrecan molecules containing G1 and/or G2 are lower in RA patients, and that RA patients have at least one specific subpopulation of aggrecan fragments, namely aggrecanse generated 374ARGSVI fragments. Further clinical studies are needed to investigate the potential of G1/G2 as a structure-related biochemical marker in destructive joint-diseases.